1 Min Read
March 15 (Reuters) - Endo International Plc
* FDA panel 18-8 to say benefits of reformulated Opana ER do not continue to outweigh its risks; 1 member abstains from voting Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.